|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rübben H, Lutzeyer W, Fischer N, Deutz F,
Lagrange W and Giani G: Natural history and treatment of low and
high risk superficial bladder tumors. J Urol. 139:283–285.
1988.PubMed/NCBI
|
|
3
|
Sharifiaghdas F and Beigi FM: Impalpable
testis: laparoscopy or inguinal canal exploration? Scand J Urol
Nephrol. 42:154–157. 2008. View Article : Google Scholar
|
|
4
|
Reuter VE: The pathology of bladder
cancer. Urology. 67(Suppl 1): 11–18. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sylvester RJ, van der Meijden AP and Lamm
DL: Intravesical bacillus Calmette-Guerin reduces the risk of
progression in patients with superficial bladder cancer: a
meta-analysis of the published results of randomized clinical
trials. J Urol. 168:1964–1970. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lamm DL, Blumenstein BA, Crissman JD, et
al: Maintenance bacillus Calmette-Guerin immunotherapy for
recurrent TA, T1 and carcinoma in situ transitional cell carcinoma
of the bladder: a randomized Southwest Oncology Group Study. J
Urol. 163:1124–1129. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davis JW, Sheth SI, Doviak MJ and
Schellhammer PF: Superficial bladder carcinoma treated with
bacillus Calmette-Guerin: progression-free and disease specific
survival with minimum 10-year followup. J Urol. 167:494–501. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nam DH, Park K, Suh YL and Kim JH:
Expression of VEGF and brain specific angiogenesis inhibitor-1 in
glioblastoma: prognostic significance. Oncol Rep. 11:863–869.
2004.PubMed/NCBI
|
|
9
|
Yoshida Y, Oshika Y, Fukushima Y, et al:
Expression of angiostatic factors in colorectal cancer. Int J
Oncol. 15:1221–1225. 1999.PubMed/NCBI
|
|
10
|
Hatanaka H, Oshika Y, Abe Y, et al:
Vascularization is decreased in pulmonary adenocarcinoma expressing
brain-specific angiogenesis inhibitor 1 (BAI1). Int J Mol Med.
5:181–183. 2000.PubMed/NCBI
|
|
11
|
Sobin LH and Wittekind C: TNM
Classification of Malignant Tumors (UICC). 6th edition. Wiley-Liss;
New York, NY: pp. 199–203. 2002
|
|
12
|
Kagan VE, Kisin ER, Kawai K, et al: Toward
mechanism-based antioxidant interventions: lessons from natural
antioxidants. Ann NY Acad Sci. 959:188–198. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuwano M, Nakamura Y and Tokino T: A novel
brain-specific p53-target gene, BAI1, containing thrombospondin
type-1 repeats inhibits experimental angiogenesis. Oncogene.
15:2145–2150. 1997. View Article : Google Scholar
|
|
14
|
Kim E and Deppert W: The versatile
interactions of p53 with DNA: when flexibility serves specificity.
Cell Death Differ. 13:885–889. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Piaton E, Faÿnel J, Ruffion A, Lopez JG,
Perrin P and Devonec M: p53 immunodetection of liquid based
processed urinary samples helps to identify bladder tumours with a
higher risk of progression. Br J Cancer. 93:242–247. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei M, Wanibuchi H, Morimura K, et al:
Carcinogenicity of dimethylarsinic acid in male F334 rats and
genetic alterations in induced urinary bladder tumors.
Carcinogenesis. 23:1387–1397. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Anderson JC, McFarland BC and Gladson CL:
New molecular targets in angiogenic vessels of glioblastoma
tumours. Expert Rev Mol Med. 10:e232008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baenziger NL, Brodie GN and Majerus PW: A
thrombin-sensitive protein of human platelet membranes. Proc Natl
Acad Sci USA. 68:240–243. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Naumov GN, Bender E, Zurakowski D, et al:
A model of human tumor dormancy: an angiogenic switch from the
nonangiogenic phenotype. J Natl Cancer Inst. 98:316–325. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Okada K, Hirabayashi K, Imaizumi T, et al:
Stromal thrombospondin-1 expression is a prognostic indicator and a
new marker of invasiveness in intraductal papillary-mucinous
neoplasm of the pancreas. Biomed Res. 31:13–19. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Greenaway J, Lawler J, Moorehead R,
Bornstein P, Lamarre J and Petrik J: Thrombospondin-1 inhibits VEGF
levels in the ovary directly by binding and internalization via the
low density lipoprotein receptor-related protein-1 (LRP-1). J Cell
Physiol. 210:807–818. 2007. View Article : Google Scholar
|
|
22
|
Dawson DW, Pearce SF, Zhong R, Silverstein
RL, Frazier WA and Bouck NP: CD36 mediates the in vitro inhibitory
effects of thrombospondin-1 on endothelial cells. J Cell Biol.
138:707–717. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dawson DW, Volpert OV, Pearce SF, et al:
Three distinct D-amino acid substitutions confer potent
antiangiogenic activity on an inactive peptide derived from a
thrombospondin-1 type 1 repeat. Mol Pharmacol. 55:332–338.
1999.PubMed/NCBI
|
|
24
|
Koh JT, Kook H, Kee HJ, et al:
Extracellular fragment of brain-specific angiogenesis inhibitor 1
suppresses endothelial cell proliferation by blocking alphavbeta5
integrin. Exp Cell Res. 294:172–184. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nicosia RF: What is the role of vascular
endothelial growth factor-related molecules in tumor angiogenesis?
Am J Pathol. 153:11–16. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kang SY and Watnick RS: Regulation of
tumor dormancy as a function of tumor-mediated paracrine regulation
of stromal TSP-1 and VEGF expression. APMIS. 116:638–647. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: Experience from a large study with
long-term follow-up. Histopathology. 41:154–161. 2002.PubMed/NCBI
|
|
29
|
Kato T, Steers G, Campo L, et al:
Prognostic significance of microvessel density and other variables
in Japanese and British patients with primary invasive breast
cancer. Br J Cancer. 97:1277–1286. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bergers G and Benjamin LE: Tumorigenesis
and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
El Moustaine D, Granier S, Doumazane E, et
al: Distinct roles of metabotropic glutamate receptor dimerization
in agonist activation and G-protein coupling. Proc Natl Acad Sci
USA. 109:16342–16347. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
New DC and Wong YH: Molecular mechanisms
mediating the G protein-coupled receptor regulation of cell cycle
progression. J Mol Signal. 2:22007. View Article : Google Scholar : PubMed/NCBI
|
